Recent advances in diagnosis and therapy of human papillomaviruses.
Infection with human papillomavirus is extremely common throughout the world. Almost 50% of sexually active young women are infected with human papillomavirus and although most infections are transient, a subset has the potential to progress to invasive cancer. During the last 20 years, our understanding of the human papillomavirus life cycle and the role of human papillomavirus in human cancer has dramatically increased. Recent technological advances in human papillomavirus detection have provided the means to detect the presence of human papillomavirus with great sensitivity. In the context of patient care, there is still substantial debate regarding the optimal diagnostic and prognostic use of information derived from hybrid capture or polymerase chain reaction-based detection. The inventory of available treatment options is growing somewhat slowly. The most promising advances are being made in the clinical evaluation of candidates for prophylactic vaccination. This review is focused on the current status and future directions of prevention, diagnosis and therapy.
Alexander
K A
KA
GlaxoWellcome, Research Triangle Park, Durham, NC 27709, USA.
Phelps
W C
WC
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000175:diagnosis* / Q000517:prevention & control / Q000628:therapy*; D015229:Sexually Transmitted Diseases, Viral / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy; D014412:Tumor Virus Infections / Q000175:diagnosis* / Q000517:prevention & control / Q000628:therapy*; D014765:Viral Vaccines
D000998:Antiviral Agents; D014765:Viral Vaccines